Eli Lilly에 대한 매도 수량은 투자자에게 Eli Lilly의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Eli Lilly (NYSE:LLY) 주식, 공매도 수량 보고

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Pharmacist,Holding,1,Tablets,(single,Dose,),Of,Contraceptive,Pill

Earnings

News

Health Care

Markets

노보 노디스크(NYSE:NVO)는 비만 치료제 위고비(Wegovy)의 알약 버전에 대한 FDA 승인을 추진하고 있다. 노보 노디스크는 최근 자사의 주사제와 유사한 안전성과 효능 수치를 보여주는 초기 데이터를 강조했다. 

노보 노디스크 &#34;위고비 알약, 평균 16.6% 체중 감소 효과...1/3은 20% 이상 감량&#34;

Jim Cramer

Equities

General

AAPL

AMZN

MSFT

SBUX

SPOT

CNBC의 짐 크레이머가 주요 기술 기업의 실적 발표와 주요 경제 업데이트로 가득한 또 다른 한 주를 투자자들에게 준비시키고 있다.지난 금요일(25일) 짐 크레이머는 이번 주 투자자들이 애플(NASDAQ:AAPL), 아마존(NASDAQ:AMZN), 메타 플랫폼스(NASDAQ:META), 마이크로소프트(NASDAQ:MSFT)의 실적 발표에 대비해야 한다고 강조했다. 또한 이번 주에는 중요한 경제 지표들도 함께 발표될 것이라고 CNBC가 보도했다.

짐 크레이머, 관세 혼란 속 주요 기술 기업 실적 발표에 대비하라 경고

Eli Lilly and Co.

Analyst Color

Biotech

Large Cap

Initiation

Analyst Ratings

캔터 피츠제럴드는 월요일(21일) 일라이 릴리(NYSE:LLY)에 대한 커버리지를 개시하면서 비만치료제 시장 지배력을 강화할 오포글리프론(orforglipron) 데이터를 인용했다.

일라이 릴리, 경구용 비만치료제로 시장 지배력 강화 준비···애널리스트 반응 긍정적

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables.
What Happened: On Wednesday, during Novo&#8217;s <a href="https://benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings">first quarter earnings</a> call, the company highlighted its upcoming oral weight loss drug, which CEO Lars Fruergaard calls &#8220;Wegovy in a pill,&#8221; and is currently under review by the U.S. Food and Drug Administration.
&#8220;If approved, this will be the first oral GLP-1 treatment for obesity in the United States,&#8221; Fruergaard said, adding that being first to market with a &#8220;known molecule, known efficacy, known safety&#8221; positions the company well in what he described as a smaller, but meaningful, segment of the market.
See More: <a href="https://www.benzinga.com/markets/equities/25/05/45275248/uber-ceo-dara-khosrowshahi-says-average-waymo-in-austin-is-busier-than-99-of-human-drivers">Uber CEO Dara Khosrowshahi Says &#8216;Average Waymo In Austin Is Busier Than 99%&#8217; Of Human Drivers</a>
Martin Lange, executive vice president of development at Novo, said the 25-milligram oral formulation &#8220;demonstrates an overall efficacy and safety profile similar to once-weekly injectable semaglutide 2.4 milligram.&#8221;
During the trial, adults struggling with obesity, who received 25 milligrams of oral semaglutide experienced &#8220;16.6% average weight loss,&#8221; Lange says, with one-third of participants experiencing weight loss of &#8220;20% of more.&#8221; Lange added that the FDA review is expected to conclude by late 2025 or early 2026.
Why It Matters: The company saw a <a href="https://benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings">big surge in Wegovy sales</a> during the first quarter, at $2.63 billion, up 85% year-over-year, as it gears up to launch the oral version of its drug.
This comes amid analyst predictions that rival Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) oral weight loss drugs can <a href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence">take share away</a> from Novo&#8217;s Semaglutide. 
During its first quarter, Novo Nordisk generated $10.9 billion in sales, missing consensus estimates at $11.64 billion, with a profit of $0.92 per share, beating estimates at $0.90. 
Price Action: The stock was up 1.90% on Wednesday, but is down 2.38% after hours following the company&#8217;s first quarter earnings release.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="137" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-1024x137.png" alt="" class="wp-image-907057" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-1024x137.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-768x103.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM-1536x205.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08011053/Screenshot-2025-05-08-at-10.40.38-AM.png 1588w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
According to Benzinga Edge Stock Rankings, Novo Nordisk has an unfavorable price trend in the short, medium, and long term. For more insights, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a>.
Photo Courtesy: kikpokemon on Shutterstock.com
Read More: <a href="https://www.benzinga.com/markets/25/05/45274831/trump-tariff-pressure-reportedly-opens-global-doors-for-elon-musks-starlink-as-nations-rush-to-show-goodwill">Trump Tariff Pressure Reportedly Opens Global Doors For Elon Musk&#8217;s Starlink As Nations Rush To Show &#8216;Goodwill&#8217;</a>

Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> during a market dip.</a>
Here's the latest transactions made by the congresswoman in early May.
What Happened: Greene was ranked as the 24th best-performing member of Congress based on their trades in 2024. The Congresswoman gained 30.2% for the year, <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">outperforming the S&amp;P 500 </a>gain of 24.9%.
With new trades placed throughout the early months of 2025, Greene could see huge returns again during the year.
Here are her most recent trades made on May 5, as shown on the <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Benzinga Government Trades page</a>. All purchases made were listed as between $1,001 to $15,000 unless otherwise indicated.
<ul>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</li>
<li>Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</li>
<li>BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)</li>
<li>BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>)</li>
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Cummins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>)</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</li>
<li>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)</li>
<li>Frontline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): two separate purchases of $1,001 to $15,000</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</li>
<li>Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</li>
<li>Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</li>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Merck Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</li>
<li>ServiceNow Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</li>
<li>Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): two separate purchases of $1,001 to $15,000</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>): two separate purchases of $1,001 to $15,000</li>
<li>Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</li>
<li>Impinj Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>)</li>
<li>Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)</li>
<li>Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</li>
<li>United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</li>
</ul>
In total, that's more than 50 different stocks bought and disclosed by Greene in the latest filing. Based on the purchase range of $1,001 to $15,000, this would make the transaction range over $50,000 and up to more than $800,000.
Read Also: <a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act">Bill Named After Nancy Pelosi Could Ban Congress Members From Trading Stocks: What You Need To Know About The &#8216;PELOSI&#8217; Act</a>
Why It's Important: Members of Congress are allowed to buy and sell stocks as long as they properly disclose the transaction.
The process has drawn scrutiny from the public and retail investors as members of Congress could have inside information and time their trades accordingly. Committee assignments in particular, often draw red flags from investors.
Greene serves on the House Committee on Oversight and Accountability and the House Committee on Homeland Security with several subcommittee appointments. The congresswoman's past trade in technology and cybersecurity stocks has drawn attention with her role within Homeland Security.
Greene&#8217;s past trades of Palantir Technologies and a<a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order"> Bitcoin ETF </a>have drawn criticism along with the timing of her trades, as she is a close ally to President Donald Trump. 
When asked previously about buying stocks earlier this year that soared days later after Trump announced a pause to tariffs, Greene<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> brushed aside the criticism.</a>
&#8220;I think that criticism is laughable. President Trump has been talking about tariffs for decades,&#8221; Greene told reporters when asked about the trades at a recent town hall event in Georgia in a clip <a href="https://x.com/unusual_whales/status/1912456434081480777" target="_blank" rel="noreferrer noopener">shared </a>by Unusual Whales. The congresswoman used the opportunity to boast about her stock performance, which ranked her as one of the top trading members of Congress in 2024.
&#8220;I don&#8217;t place my buys and sells," Greene said, citing an agreement she has with her portfolio manager, who handles all the buying and selling of stocks. &#8220;He did a great job. Guess what he did. He bought the dip. And that&#8217;s what anybody that has financial sense does."
Greene also said her portfolio manager did not have inside information, everything was public and a potential tariff pause wasn&#8217;t a secret.
Sen. Josh Hawley (R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at the congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).  
&#8220;Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents,&#8221; Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. &#8220;Americans have seen politician after politician turn a profit using information not available to the general public.&#8221;
Hawley said the bill will help &#8220;restore Americans&#8217; trust in our nation&#8217;s legislative body.&#8221;
Hawley&#8217;s bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
&#8220;Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it,&#8221; Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it&#8217;s important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;it is both Republican</a>&nbsp;and Democratic members of Congress who are profiting from buying and selling stocks and options while in office, with some trades coming with questionable timing or having a connection to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png" alt="" class="wp-image-906796" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo: Shutterstock

Government

Politics

ABBV

ADBE

AMAT

DELL

GILD

GOOG

INTC

MELI

NVDA

ODFL

PANW

PAYX

QCOM

SCHW

TSLA

Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Wednesday reported first-quarter 2025 sales of roughly $10.89 billion (78.09 billion Danish kroner), missing the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $11.64 billion</a>.
Sales increased by 19% in Danish kroner and 18% at CER. In U.S. Operations, sales increased by 20% in Danish kroner and 17% at CER.
Sales in International Operations increased by 18% measured in Danish kroner and by 19% at CER. Sales growth has resulted in periodic supply constraints and related drug shortage notifications for certain products and geographies.
The weight loss drug maker <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915255" rel="noreferrer noopener">reported</a> Q1 adjusted EPS of 92 cents, beating the consensus of 90 cents.
The company reported an adjusted net profit of 30.3 billion in the quarter, which was up 15% year over year.
Ozempic&nbsp;<a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/5fa26f83-a579-42fc-a3bf-242fe76a5f3e" rel="noreferrer noopener">sales</a> increased 18% to 32.72 billion Danish kroner, and Wegovy sales jumped 85% to 17.36 billion Danish kroner.
The company added that the volume of compounded GLP-1s in the U.S. is estimated to have impacted the uptake of Wegovy prescriptions and the growth of the <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">branded obesity market</a> during the first quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45147328/cvs-caremark-to-place-novo-nordisks-wegovy-on-preferred-coverage-for-glp-1-weight-loss-treatment" rel="noreferrer noopener">CVS Caremark To Place Novo Nordisk&#8217;s Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment</a>
Insulin sales increased 4% to 14.9 billion Danish kroner, and Rare disease sales increased 5% to 4.62 billion Danish kroner.
Sales in Diabetes care increased by 10% and 8% at CER to 55.04 billion. Novo Nordisk&#8217;s global diabetes value market share decreased by 0.6% over the last 12 months to 33.3%, driven by market share losses in the U.S. and International Operations.
In IO countries, Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide is categorised under GLP-1 diabetes only in IQVIA data, despite having indications for Diabetes and Obesity in most launched countries.
In its earnings release, Novo Nordisk said it submitted a Supplemental New Drug Application (sNDA) to the U.S. FDA in February for the PDS290 device variant for Wegovy. The company expects the regulatory review to be completed around mid-year 2025.
In February 2025, Novo Nordisk submitted oral semaglutide 25 mg to the FDA, with the potential to be the first oral GLP-1 treatment for obesity.
The submission is based on OASIS 4, a 64-week efficacy and safety trial comparing once-daily oral semaglutide 25 mg to placebo in 307 adults with obesity or overweight with one or more comorbidities.
In adults with obesity or overweight, oral semaglutide 25 mg achieved a 16.6% weight loss from a baseline bodyweight of 105.9 kg compared to a 2.7% reduction with placebo.
Novo Nordisk expects the regulatory review to be completed around the turn of the year.
<h2 class="wp-block-heading">Guidance For 2025</h2>
Novo Nordisk lowered its 2025 sales <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">growth from 16%-24%</a> to 13%-21% at CER and operating profit growth of 16%-24%, down from 19%-27% at CER.
Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.
The updated sales outlook reflects lower-than-planned penetration of branded GLP-1 treatments in the U.S., impacted by compounded GLP-1s.
Price Action: At the last check on Wednesday, NVO stock was up 5.49% at $69.93 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Guidance

Movers

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook

Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now staring at a bankruptcy process to reorganize its finances. 
What Happened: In a press release on Tuesday, the company announced that it has voluntarily initiated a "pre-packaged" Chapter 11 bankruptcy filing in Delaware. It aims to complete the court-supervised reorganization process within 45 days, &#8220;if not sooner.&#8221;
It plans to eliminate $1.15 billion in debt on its books through this process, helping &#8220;position WeightWatchers for long-term growth and success,&#8221; as it transitions into a telehealth services provider.
See More: <a href="https://www.benzinga.com/25/05/45242461/donald-trumps-trade-war-sparks-first-major-us-china-talks-scott-bessent-jamieson-greer-to-meet-chinese-delegation-in-geneva">Scott Bessent To Meet Chinese Officials For Crucial Trade Talks In Switzerland: Trump Administration</a>
The company says that it will remain fully operational during this reorganization process, and that there will be no impact on its members or the plans they rely on. 
WW International&#8217;s CEO, Tara Comonte, says, &#8220;The decisive actions we're taking today, with the overwhelming support of our lenders and noteholders, will give us the flexibility to accelerate innovation, reinvest in our members, and lead with authority in a rapidly evolving weight management landscape.&#8221;
Once <a href="https://www.benzinga.com/news/earnings/24/02/37379284/weightwatchers-stock-falls-after-q4-results-oprah-winfrey-exits">backed by talk show host</a> Oprah Winfrey, it has been under increasing pressure in recent years amid the rising popularity of GLP-1 drugs like Wegovy and Ozempic, manufactured by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), which many consumers see as a more convenient alternative to counting points and calories, according to a <a href="https://edition.cnn.com/2025/05/06/business/weight-watchers-bankruptcy">report</a> by CNN.
Why It Matters: The move to file for bankruptcy comes amid investor Bruce Galloway building a 3% stake in the company two weeks ago, before urging the management not to file for bankruptcy, in a letter addressed to Comonte.
&#8220;We believe [that] if the company files Chapter 11, this will significantly impair the shareholders and be an extreme breach of the Board and Management's fiduciary duty and responsibility,&#8221; he said, before suggesting that the company pursue an out-of-court restructuring by offering equity to debt holders, citing the recent example of Regis Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGS#NASDAQ">RGS</a>).
The company has made several efforts over the years to stay relevant in this rapidly changing weight-loss landscape, with the <a href="https://www.benzinga.com/news/small-cap/23/03/31244013/looking-to-shed-some-pounds-weightwatchers-to-offer-weight-loss-drugs-like-ozempic">most prominent one</a> being its acquisition of telehealth provider, Sequence, which can prescribe popular weight-loss drugs such as Wegovy, Ozempic, and Trulicity. 
It also <a href="https://www.benzinga.com/news/25/04/45073094/weightwatchers-integrates-with-eli-lilly-to-expand-access-to-zepbound-stock-skyrockets-110">entered into a partnership</a> with Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) recently, in order to give its members access to the latter&#8217;s weight-loss drug, Zepbound. 
Price Action: The stock was up 11.20% on Tuesday, but is down nearly 57% after hours, following the company&#8217;s announcement to file for bankruptcy.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="133" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06223429/Screenshot-2025-05-07-at-8.04.12-AM-1024x133.png" alt="" class="wp-image-904659" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06223429/Screenshot-2025-05-07-at-8.04.12-AM-1024x133.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06223429/Screenshot-2025-05-07-at-8.04.12-AM-300x39.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06223429/Screenshot-2025-05-07-at-8.04.12-AM-768x100.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06223429/Screenshot-2025-05-07-at-8.04.12-AM-1536x200.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06223429/Screenshot-2025-05-07-at-8.04.12-AM.png 1596w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Despite its woes, WW International has a favorable price trend in the short term, according to Benzinga Edge Stock Rankings. For more insights, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a>.
Photo Courtesy: Jonathan Weiss On Shutterstock.com
Read More: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/05/45240439/ive-made-no-sacrifice-warren-buffett-has-given-away-60-billion-but-says-giving-time-is-more-admirable-ive-done-little-of-that">&#8216;I&#8217;ve Made No Sacrifice&#8217; — Warren Buffett Has Given Away $60 Billion But Says Giving Time Is More &#8216;Admirable&#8217;: &#8216;I&#8217;ve Done Little Of That&#8217;</a></li>
</ul>

Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected

The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">American consumers and patients</a>.
This change builds upon the agency&#8217;s Office of Inspection and Investigations&#8217; Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies.&nbsp;
&#8220;For too long, foreign companies have enjoyed a double standard—given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning,&#8221; said FDA Commissioner Martin Makary. &nbsp;
On Tuesday, the FDA <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">said</a> it plans to review and improve its foreign inspection program to ensure it meets the highest standards for oversight. Part of this effort includes making it clear that FDA inspectors should not accept travel-related perks like hotel stays or transportation from the companies they inspect.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45225204/iqvia-beats-q1-earnings-expectations-despite-sector-uncertainty-company-navigating-market-conditions-effectively-says-ceo" rel="noreferrer noopener">IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions &#8216;Effectively&#8217; Says CEO</a>
The FDA conducts about 12,000 inspections annually in the U.S. and 3,000 in other countries. While U.S. companies often get surprise inspections, foreign companies usually receive advanced notice, giving them time to prepare and potentially hide problems.
Still, foreign inspections often reveal serious issues, more than twice as often as domestic ones.
In the U.S., inspections are usually unannounced unless specific programs require advance notice to ensure staff and records are available.
Even then, companies can&#8217;t pick the date or time. The FDA says foreign companies shouldn&#8217;t have that option either.
By shifting to more surprise inspections abroad, the FDA aims to better protect American consumers by catching dishonest practices, like falsifying records or hiding violations, before they cause harm.
The agency can take action against any company that tries to delay, block, or refuse an unannounced inspection.
The update follows President&nbsp;Donald Trump&#8217;s signed executive order on Monday to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The order directs the FDA to reduce the amount of time it takes to approve manufacturing plants in the U.S. by eliminating unnecessary requirements, streamlining reviews, and working with domestic drugmakers to &#8220;provide early support before facilities come online,&#8221; <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/" rel="noreferrer noopener">according</a> to&nbsp;a White House fact sheet.
It also directs the agency to raise inspection fees for foreign manufacturing plants, improve the enforcement of active-ingredient source reporting by overseas producers, and consider publicly listing facilities that don&#8217;t comply.
The White House <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" rel="noreferrer noopener">estimates</a> that it can currently take five to ten years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint.&#8221;
<a target="_blank" href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs" rel="noreferrer noopener">Amid tariff uncertainty</a>, many companies have disclosed a wave of investments in recent months to boost production in the U.S.
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) did not highlight investments in new manufacturing plants; it noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">their products in the U.S</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Most recently, Bristol-Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Stat this week.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45195137/footwear-titans-nike-adidas-call-tariffs-an-existential-threat-appeal-to-trump-for-relief-this-is-an-emergency" target="_blank" rel="noreferrer noopener">Footwear Titans Nike, Adidas Call Tariffs An &#8216;Existential Threat&#8217;, Appeal To Trump For Relief: &#8216;This Is An Emergency&#8217;</a></li>
</ul>
Photo by Tada Images via Shutterstock

Regulations

REGN

RHHBY

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">boosting domestic drug manufacturing</a>.
What To Know: President Donald Trump signed a new executive order late Monday that aims to reshape the pharmaceutical supply chain by incentivizing drug manufacturers in the U.S., according to <a href="https://www.cnbc.com/2025/05/05/trump-order-us-drug-manufacturing.html">CNBC.</a>
The order calls on federal agencies to speed up approval for U.S.-based manufacturing facilities, increase inspection fees on overseas drugmakers and streamline permitting through a coordinated, centralized process. 
The executive order directs the FDA to increase fees for foreign manufacturing plants and proposes publicizing facilities that fail to meet compliance standards. A key provision calls for &#8220;surprise&#8221; inspections abroad, ending the practice of giving advance notice to international sites, which U.S. plants are already subject to.
The policy shift comes as pharmaceutical imports into the U.S. remain high with $203 billion in imports in 2023 alone. Nearly 75% of the imported pharmaceutical products in 2023 came from Europe, mainly Ireland, Germany and Switzerland.
Although Eli Lilly manufactures a lot of its products in the U.S., the company has significant operations and investments in both Ireland and Germany. Eli Lilly also imports a lot of its pharmaceutical ingredients, however, the company <a href="https://www.benzinga.com/content/44189496/eli-lilly-pours-27b-into-u-s-growth-what-it-means-for-investors">announced plans</a> in February to invest $27 billion in U.S. manufacturing, with most plants focused on pharmaceutical ingredient manufacturing.
The new executive order aims to reduce this dependency by encouraging U.S.-based production, which government officials argue is essential for national security and supply chain resilience.
Drugmakers such as Eli Lilly could face cost pressures from the realignment. The Trump administration is also preparing to <a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market">announce tariffs</a> on imported pharmaceuticals, adding another layer of uncertainty for companies with global supply chains. Several pharmaceutical stocks appear to be moving lower in response to the announcement and the potential implications for operating costs and regulatory compliance.
LLY Price Action: Eli Lilly shares were down 6.06% at $771.69 at the time of publication Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/05/45231535/stocks-fall-on-trade-concerns-oil-and-gold-rally-whats-driving-markets-tuesday">Stocks Fall On Trade Concerns, Oil And Gold Rally: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image via Shutterstock.

Global

Eli Lilly Stock Is Sliding Tuesday: What's Going On?

President Donald Trump signed an executive order Monday directing the Food and Drug Administration to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to <a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market">announce new tariffs on imported medicines</a> within two weeks.
What Happened: The executive order aims to streamline the drug manufacturing approval process by eliminating unnecessary requirements and reducing the time needed to approve new U.S. production sites. 
According to the White House, building pharmaceutical manufacturing capacity currently takes &#8220;five to 10 years,&#8221; which it called &#8220;unacceptable from a national-security standpoint.&#8221;
&#8220;We don&#8217;t want to be buying our pharmaceuticals from other countries because if we&#8217;re in a war, we&#8217;re in a problem, we want to be able to make our own,&#8221; Trump said in a White House fact sheet.
See Also: <a href="https://www.benzinga.com/markets/25/05/45213562/peter-schiff-challenges-us-dominance-after-elon-musks-china-consumption-narrative-a-50-drop-in-the-dollar-could-supercharge-chinas-global-consumer-base">Peter Schiff Challenges US Dominance After Elon Musk&#8217;s China Consumption Narrative — A 50% Drop In The Dollar Could Supercharge China&#8217;s Global Consumer Base</a>
Why It Matters: The executive order comes as U.S. pharmaceutical manufacturing has significantly declined over decades, with most active drug ingredients now produced in China and other countries. According to EY analysis, reported by Reuters, the U.S. imported $203 billion in pharmaceutical products in 2023, with 73% coming from Europe, primarily Ireland, Germany and Switzerland.
For investors, this points to broader <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target">shifts in the pharmaceutical secto</a>r, with companies such as Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) already unveiling new domestic manufacturing plans in reaction to the looming tariff threats.
The pending tariffs could significantly impact <a href="https://www.benzinga.com/personal-finance/25/04/45029761/experts-warn-tariffs-could-negatively-impact-pretty-fragile-supply-of-generic-drugs">generic drug makers</a>, which provide 90% of U.S. prescriptions, possibly worsening existing shortages. There are already over 250 drug shortages nationwide, down from 323 in early 2024 but still concerning for healthcare stakeholders.
Mark Cuban, whose Cost Plus Drugs company sells medications at substantial discounts, warned the tariffs could force <a href="https://www.benzinga.com/news/25/04/44658207/mark-cuban-says-cost-plus-drugs-faces-price-hike-threat-tariffs-would-force-us-to-pass-costs-directly-to-consumers">price increases on many drugs</a>: &#8220;If we have a high tariff on drugs coming from India, we won&#8217;t have a choice but to pass those costs on to consumers.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45213365/maxine-waters-to-obstruct-cryptocurrency-hearing-plans-shadow-hearing-instead">Maxine Waters Plans Walkout From Crypto Hearing, Will Host &#8216;Shadow Hearing&#8217; Opposing Trump Family Ventures: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns

<a href="https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE">https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE</a>
President Donald Trump will sign an executive order Monday to streamline regulations surrounding pharmaceutical manufacturing in the United States, according to two White House officials who spoke on the condition of anonymity to describe plans that have not been made public.
The order to incentivize domestic drug manufacturing comes ahead of possible <a href="https://www.washingtonpost.com/business/2025/04/10/tariffs-pharmaceuticals-us-drugs-cost/">tariffs on pharmaceuticals</a> — a policy that's on hold, for now, pending an investigation by the Commerce Department to determine whether importing pharmaceuticals is a threat to national security. That Section 232 investigation could be completed this summer, one of the officials said Monday.
But regardless of whether the Trump administration puts tariffs on prescription drugs, Monday's executive order seeks to incentivize more domestic manufacturing of medications.

BNTX

MRNA

'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets rebounded this week, fully recovering losses incurred since President Donald Trump's April 2 tariff escalation. The S&amp;P 500, Dow Jones and Nasdaq each rose by more than 1.3%, with Friday marking the S&amp;P 500's ninth consecutive daily gain — the longest streak since 2004.
The rally was fueled by a stronger-than-expected April jobs report, with 177,000 jobs added, surpassing forecasts of 135,000. Unemployment remained at 4.2%, and sectors like healthcare and transportation led job growth. However, Q1 GDP contracted by 0.3%, the largest drop since 2022, largely due to a surge in imports ahead of tariff implementations.
Corporate earnings contributed to market optimism. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) exceeded Wall Street estimates, with Microsoft posting its best weekly performance in years. Despite these gains, concerns linger about the long-term economic impact of tariffs, as businesses face uncertainty and potential cost increases.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.
The Bulls
<a href="https://www.benzinga.com/general/biotech/25/05/45136276/mounjaro-maker-eli-lilly-clocks-45-jump-in-q1-revenue-cuts-2025-profit-outlook-but-not-due-to-tariffs">"Mounjaro maker Eli Lilly clocks 45% jump in Q1 revenue, cuts 2025 profit outlook but not due to tariffs"</a>, by Vandana Singh, reports that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) posted a 45% year-over-year revenue increase to $12.73 billion in Q1 2025, driven by strong sales of Mounjaro and Zepbound, but lowered its 2025 EPS forecast to $20.78-$22.28 due to a $1.57 billion charge related to acquired in-process R&amp;D, clarifying that the guidance does not account for potential future tariff changes.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45137383/microsoft-rallies-after-crushing-q3-earnings-goldman-sachs-lifts-target-to-480">"Microsoft rallies after crushing Q3 earnings, Goldman Sachs lifts target to $480"</a>, by Piero Cingari, reports that Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) beat Q3 estimates with $70.07 billion in revenue and $3.46 EPS, driven by a 35% surge in Azure revenue — 16 points of which came from AI services — prompting Goldman Sachs analyst Kash Rangan to raise the price target to $480.
<a href="https://www.benzinga.com/news/earnings/25/04/45038400/plug-power-rallies-as-new-financing-cost-cuts-boost-confidence-in-turnaround-plan">"Plug Power rallies as new financing, cost cuts boost confidence in turnaround plan"</a>, by Anusuya Lahiri, reports that Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares rose after the company secured a $525 million debt facility and implemented cost-cutting measures expected to yield over $200 million in annual savings, signaling progress toward profitability.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/trading-ideas/movers/25/04/45120603/amazon-stock-is-rising-after-the-bell-whats-driving-the-action">Amazon Stock Is Rising After The Bell: What's Driving The Action?</a>
<a href="https://www.benzinga.com/news/earnings/25/04/45120458/bloom-energy-reports-better-than-expected-q1-results-details">Bloom Energy Reports Better-Than-Expected Q1 Results: Details</a>
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a>
The Bears
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45175831/apple-stock-faces-tariff-related-headwinds-4-analysts-break-down-q2-results-whats-next">"Apple stock faces tariff-related headwinds: 4 analysts break down Q2 results, what's next"</a>, by Chris Katje, reports that Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) exceeded Q2 expectations with $95.4 billion in revenue and $1.65 EPS, but analysts from Needham, Goldman Sachs and Bank of America warn that escalating U.S.-China tariffs — projected to cost Apple $900 million in the June quarter — pose ongoing risks to product margins and earnings.
<a href="https://www.benzinga.com/news/earnings/25/04/45084597/starbucks-misses-q2-earnings-estimates-ceo-says-optimism-has-turned-into-confidence-i-see-more-opportunity-than-i-imagined">"Starbucks Misses Q2 Earnings Estimates, CEO Says Optimism Has Turned Into Confidence: ‘I See More Opportunity Than I Imagined'"</a>, by Adam Eckert, reports that Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) posted Q2 revenue of $8.76 billion and adjusted EPS of 41 cents — both below analyst expectations — while CEO Brian Niccol expressed confidence in the company's "Back to Starbucks" turnaround plan, highlighting operational improvements and customer experience enhancements.
<a href="https://www.benzinga.com/news/earnings/25/04/45106948/norwegian-cruise-line-tumbles-after-earnings-miss-still-confident-in-2025-guidance">"Norwegian Cruise Line Tumbles After Earnings Miss, Still Confident In 2025 Guidance"</a>, by Akanksha Bakshi, reports that Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) shares fell after the company missed Q1 2025 revenue and earnings estimates, citing a 2.9% revenue decline to $2.13 billion and adjusted EPS of $0.07, but reaffirmed its full-year guidance of $2.05 EPS and $2.72 billion in adjusted EBITDA, despite softening forward bookings amid macroeconomic headwinds.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/news/earnings/25/05/45152870/bigbear-ai-shares-slide-after-worse-than-expected-q1-report">BigBear.ai Shares Slide After Worse-Than-Expected Q1 Report</a>
<a href="https://www.benzinga.com/trading-ideas/technicals/25/04/45072193/stock-of-the-day-abbvies-rally-looks-stretched-could-a-reversal-be-next">Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?</a>
<a href="https://www.benzinga.com/25/04/45086922/whats-going-on-with-restaurant-chain-owner-brinkers-stock-today">Why Did Chili's Restaurant Parent Brinker International Stock Tumble On Tuesday?</a>
Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

BBAI

NCLH

PLUG

Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Losses

UBS analyst Trung Huynh maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and lowers the price target from $1100 to $1050.

Price Target

UBS Maintains Buy on Eli Lilly, Lowers Price Target to $1050

Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Thursday reported first-quarter earnings and <a href="https://www.benzinga.com/general/biotech/25/04/45112166/eli-lilly-stock-has-the-technicals-will-q1-earnings-deliver-fundamentals" target="_blank" rel="noreferrer noopener">lowered its 2025 guidance</a>.
The U.S. pharma giant reported January-March revenue of $12.73 billion, up 45% year over year and almost in line with the <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">consensus of $12.67 billion</a>. That was driven by a 53% increase in volume, partially offset by a 6% hit from lower realized prices and a 2% unfavorable impact of <a href="https://www.benzinga.com/general/biotech/25/05/45136276/mounjaro-maker-eli-lilly-clocks-45-jump-in-q1-revenue-cuts-2025-profit-outlook-but-not-due-to-tariffs" target="_blank" rel="noreferrer noopener">foreign exchange rates</a>.
Key Products revenue grew by&nbsp;$4.09 billion&nbsp;to&nbsp;$7.52 billion&nbsp;in Q1 2025, led by Mounjaro and Zepbound.
Eli Lilly reaffirmed its fiscal year 2025 <a href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines" target="_blank" rel="noreferrer noopener">sales guidance of $58 billion—$61 billion</a> versus a market consensus of $59.52 billion and $45.04 billion in 2024.
But it lowered the 2025 adjusted EPS outlook from $22.50-$24.00 to $20.78-$22.28, compared to the street consensus of $21.93, to reflect the impact of the Q1 2025 acquired IPR&amp;D.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45051380/plaintiff-sues-eli-lilly-johnson-johnson-over-alleged-breast-cancer-risk-linked-to-antipsychotic-medications" rel="noreferrer noopener">Plaintiff Sues Eli Lilly, Johnson &amp; Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications</a>
Goldman Sachs analysts wrote in a note that Eli Lilly&#8217;s &#8220;decent set of 1Q25 results was overshadowed by <a href="https://www.benzinga.com/general/biotech/25/05/45147328/cvs-caremark-to-place-novo-nordisks-wegovy-on-preferred-coverage-for-glp-1-weight-loss-treatment" target="_blank" rel="noreferrer noopener">news of a formulary change announcement</a> by CVS Caremark that it is dropping the company&#8217;s Zepbound in favor of Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy.&#8221;
&#8220;This has raised investor questions about pricing dynamics across the anti-obesity medication market. The combined price action in Eli Lilly and Nov Nordisk suggests investors are pondering smaller obesity TAM assumptions on pricing concerns. We believe these concerns are excessive,&#8221; Goldman analyst Asad Haider wrote.
Eli Lilly&#8217;s tirzepatide franchise strength, along with the robust orforglipron program for oral obesity, would have been rewarded had it not been for the CVS announcement, according to the Wall Street firm.
Haider maintains a buy rating on Eli Lilly and views the company as a leader in the anti-obesity market. According to the analyst, &#8220;sharp selloffs in LLY shares have presented a buying opportunity.&#8221;
Goldman Sachs lowered its Eli Lilly <a href="https://www.benzinga.com/quote/LLY/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $888 to $883</a> on Friday, reflecting PBM-related uncertainty.
BofA Securities on Friday noted Eli Lilly says it's reluctant to take part in &#8220;one-on-one&#8221; negotiations with insurers—where only one drug is chosen and companies are forced to compete head-to-head. The company believes it doesn't need to do that because Zepbound is a superior product.
&#8220;We think this whole CVS issue probably got more attention than it deserved&#8230;The CVS news does not mark a major, new negative trend, but does reflect the reality that no company ever has all payers locked up,&#8221; BofA Securities analyst Tim Anderson wrote.
BofA reiterates the Buy rating with a price target of $1,000.
Price Action: LLY stock is up 4.10% at $826.64 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45170433/kimberly-clark-commits-2b-to-us-expansion-overhaul" target="_blank" rel="noreferrer noopener">Kimberly-Clark Commits $2 Billion For US Expansion Overhaul</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 30 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $567,219, and 23 were calls, valued at $1,284,934.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $600.0 to $1380.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 566.85, with a total volume reaching 2,133.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $600.0 to $1380.0, throughout the last 30 days.
<h3>Eli Lilly 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746194447_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$62.35</td>
<td>$62.25</td>
<td>$62.25</td>
<td>$710.00</td>
<td>$242.6K</td>
<td>6</td>
<td align="right">39</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/02/25</td>
<td>$26.95</td>
<td>$21.9</td>
<td>$23.97</td>
<td>$800.00</td>
<td>$179.7K</td>
<td>558</td>
<td align="right">92</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.65</td>
<td>$8.4</td>
<td>$8.65</td>
<td>$860.00</td>
<td>$173.0K</td>
<td>566</td>
<td align="right">232</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.2</td>
<td>$8.7</td>
<td>$8.7</td>
<td>$920.00</td>
<td>$130.5K</td>
<td>1.8K</td>
<td align="right">155</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$800.00</td>
<td>$127.5K</td>
<td>763</td>
<td align="right">185</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>With a volume of 1,063,466, the price of LLY is up 4.39% at $829.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 97 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $923.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Eli Lilly, maintaining a target price of $1124. 
&#x2A; In a positive move, an analyst from Goldman Sachs has upgraded their rating to Buy and adjusted the price target to $888. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $975. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on Eli Lilly, maintaining a target price of $928. 
&#x2A; Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new price target of $700.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Eli Lilly's Options Frenzy: What You Need to Know

U.S. stock futures are in the green early Friday, after another winning day for the markets in the regular session on Thursday.
What Happened: The futures markets continue to inch higher following fresh signals from China that it is open to begin trade negotiations with Washington after weeks of stonewalling.
Strong earnings performance by Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Airbnb Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), amid growing trade, tariff, and geopolitical headwinds, helped lift investor sentiments following weeks of turbulence and uncertainties.
On Friday, investors will be closely watching the earnings of Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), and Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), among several others.
U.S. 10-Year Treasuries are at 4.20%, while the 2-Year Treasuries are at 3.69%. The CME Group's FedWatch&nbsp;<a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html" target="_blank" rel="noreferrer noopener">tool</a>&nbsp;shows the markets pricing a 93.2% likelihood of interest rates remaining unchanged during the FOMC meeting that is scheduled to take place the first week of May, which marks a decrease from 95% on Thursday.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Futures</td>
<td class="has-text-align-center" data-align="center">Change (+/-)</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">0.54%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">0.50%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq 100</td>
<td class="has-text-align-center" data-align="center">0.34%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">1.01%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> The&nbsp;SPDR S&amp;P 500 Trust ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.71% on Monday, while the&nbsp;Invesco QQQ Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq-100 Index, was up 1.31%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;138z7gr&#x2A;_gcl_au&#x2A;MjA5Njc0MjY1My4xNzQwODM2NTUw&#x2A;_ga&#x2A;R1MxLjEuMTc0NDY0ODA3Mi4yLjAuMTc0NDY0ODA3NS4wLjAuMA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NTgyOTMzMy4xLjEuMTc0NTgyOTYyMy4wLjAuMA..">Benzinga Pro</a>&nbsp;data. Cues From Last Session: The markets were upbeat on Thursday, with most S&amp;P 500 sectors in the green, with tech and consumer discretionary sectors leading the charge. Healthcare, however, witnessed a steep decline, down 2.73% during the day, owing to the 11.66% pullback in Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), following its first quarter earnings. The S&amp;P 500 itself was up 0.63% during the day, closing at 5,604.14, followed by the Nasdaq Composite at 17,710.74, up 1.52%, the Dow Jones Industrial Average at 40,752.96, up 0.21%, and the small-cap gauge, Russell 2000, which was up 0.60%, closing at 1,975.86. Initial jobless claims at 241,000 came in significantly higher than the median forecast of 225,000, which soured sentiments during the day. As of Thursday, the Nasdaq 100 index was down 10.96% from its previous high of 22,222.61 points. The S&amp;P 500 index was 8.83% lower, as compared to the last record high of 6,147.43 points. On the other hand, Dow Jones was down 9.58% from its 52-week high of 45,073.63 points.</figcaption></figure>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Index</td>
<td class="has-text-align-center" data-align="center">Performance (+/-)</td>
<td class="has-text-align-center" data-align="center">Value</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq Composite</td>
<td class="has-text-align-center" data-align="center">1.52%</td>
<td class="has-text-align-center" data-align="center">17,710.74</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">0.63%</td>
<td class="has-text-align-center" data-align="center">5,604.14</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">0.21%</td>
<td class="has-text-align-center" data-align="center">40,752.96</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">0.60%</td>
<td class="has-text-align-center" data-align="center">1,975.86</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to analyst Seth Golden, a chief market strategist at the Finom Group, the S&amp;P 500 having retraced 50% of the bear market at closing on Thursday, points towards the markets going to their all-time high.
Golden says, &#8220;Since 1956, when this occurred, the index went on to all-time highs and was higher 12 months forward 100% of the time.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It&#39;s official &#x2705; S&amp;P 500 has retraced 50% of the bear market on closing basis. Since 1956, when this occurred, the index went on to all-time highs and was higher 12 months forward 100% of the time! Only time the low was not in was 2022 (Jackson Hole &quot;more pain to come&quot;)<a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a>… <a href="https://t.co/CeiiVqmdks">pic.twitter.com/CeiiVqmdks</a>
&mdash; Seth Golden (@SethCL) <a href="https://twitter.com/SethCL/status/1918106892418580919?ref_src=twsrc%5Etfw">May 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The only time this didn&#8217;t happen, says Golden, was in 2022, when Fed Chair Jerome Powell made his infamous &#8220;more pain to come&#8221; speech, leading to steeper declines in the market.
Upcoming Economic Data:
<ul>
<li>U.S. Non-Farm Payrolls, U.S. Unemployment Rate, U.S. Hourly Wages, and Hourly Wages Year-Over-Year are all set to be announced by 8:30 AM ET on Friday. </li>
<li>Factory Orders report for March is scheduled to be announced by 10 AM ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) is set to release its earnings on Friday, and while there is no clarity on the timing of the announcement, the stock is up 1.12% pre-market. Analysts expect the company to report $4.72 per share in earnings, on $81.59 billion in revenue. </li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) will be releasing its earnings at 9:30 AM, with analysts expecting $1.73 per share earnings, on $86.1 billion in revenue. The stock is up 0.87% pre-market. </li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) is scheduled to announce its first quarter earnings by 11:00 AM, with consensus estimates pegging its earnings at $2.15 per share, on $48.4 billion in revenue. The stock is up 0.66% pre-market. </li>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) will be releasing its first quarter earnings before markets open at 8:30 AM, with the stock trading up 1.16% pre-market. Analysts expect $6.35 earnings per share, on $60.4 billion in revenue. </li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) is up 1.23% pre-market, with the company expected to release its first quarter earnings before markets open at 8:30 AM. Analysts expect $1.84 in earnings, on $964 million in revenue.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures are down for the day by 0.65%, trading at $58.87 per barrel, amid growing concerns of a recession and oversupply.
Gold Spot US Dollar has finally broken free from its losing streak, and is up 1.31% on Friday, trading at $3,259.42 per ounce, which is still considerably lower than $3,500.33 per ounce last week. The U.S. Dollar Index is down 0.48%, trading at 99.7175 at the time of writing.
All Asian, Australian, and New Zealand markets are in the green on Friday, barring China&#8217;s Shanghai Index which is marginally lower. 
Image via Shutterstock

ABNB

US Futures Rise As Apple, Amazon, Airbnb Earnings Boost Market Sentiment: S&P 500 Hits Milestone That's Preceded A 100% Win Rate Since 1956, Says Expert

Editor&#8217;s Note: The article has been udpated to correct the Stock Movers list.
Wall Street pushed higher in midday trading, with the S&amp;P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced <a href="https://www.benzinga.com/topic/tariffs">trade tariffs on April 2.</a>
Technology stocks led the rally, with the Nasdaq 100 climbing 1.5%. Strong and resilient corporate earnings continue to fuel investor appetite for risk, helping markets shrug off recent tariff concerns.
President Trump reassured investors, stating that progress on trade negotiations is going "very well" and that the timeline for the tax bill remains on schedule.
On the economic front, data continued to paint a weaker picture. After Wednesday's disappointing first-quarter GDP report, the ISM manufacturing PMI showed factory activity contracted for the second straight month in April. Meanwhile, price pressures surged at the fastest pace since June 2022, reflecting <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45139383/us-manufacturing-activity-contracts-in-april-as-tariffs-push-input-prices-toward-3-year-highs">inflationary effects from tariffs.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) was a standout gainer, soaring 8.60% after delivering a blowout quarter that beat expectations across the board, reinforcing its leadership in cloud and AI. The stock reached its highest level since late January.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) also topped estimates, with shares climbing more than 4%.
Sector-wise, technology outperformed, while health care lagged. Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plunged over 9% after the pharmaceutical giant cut its 2025 guidance.
Crude oil erased early losses, rebounding to $58 per barrel after briefly dipping below $57. Gold slipped 2.2% to a two-week low.
The U.S. dollar strengthened to its highest level in over two weeks, bolstered by manufacturing surveys showing rising input costs tied to tariffs.
Treasury yields climbed for a second straight session, with the 10-year yield rising to 4.21%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged past the $97,000 mark, hitting its highest level in over two months.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,853.70</td>
<td>+ 1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.89</td>
<td>+ 0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,971.76</td>
<td>+ 0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,802.25</td>
<td>+ 0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1% to $560.02.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $408.25.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 1.6% to $483.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.5% higher to $195.71.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 2.6%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.3%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: Microsoft Corporation: up 8.30% Meta Platforms, Inc.: up 4.29% Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): &#8211; 9.88% Mastercard Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>): -0.20% McDonald's Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): -1.24% Linde plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>): -1.14% Qualcomm Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>): -8.28% KKR &amp; Co. Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): up 1.19% The Southern Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>): up 0.22% Intercontinental Exchange, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): up 1.83% KLA Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>): -2.43% CVS Health Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 6.23% Equinix, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): -0.16% Parker-Hannifin Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>): up 0.70% Air Products and Chemicals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>): -0.09% Howmet Aerospace Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>): up 7.44% Carrier Global Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): up 11% Aflac Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>): -4% Public Storage&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>): -0.18% The Allstate Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>): -1.27% MetLife, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>): up 0.47% W.W. Grainger, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>): Up 2.14% Becton, Dickinson and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>): -15.73% Quanta Services, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>): up 10.10% Exelon Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): -0.33% Dominion Energy, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.91%
Stocks slated to report earnings after the bell include Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>), Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Consolidated Edison Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>), Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>), DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), Ameren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>), GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>), Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>), Camden Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) and Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45117801/apple-q2-earnings-preview-analysts-remain-bullish-with-caution-of-tariff-tornado-hitting-iphone">Apple Q2 Earnings Preview: Analysts Remain Bullish But Warn Of &#8216;Tariff Tornado&#8217; Hitting iPhone</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AMGN

CARR

SPDR Dow Jones Industrial Average ETF Trust

DXCM

EQIX

GDDY

HOLX

KLAC

MPWR

MSTR

TEAM

Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday? (CORRECTED)

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$2.00</td>
<td>$30.8K</td>
<td align="right">332</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$820.00</td>
<td>$35.4K</td>
<td align="right">141</td>
<td>1.1K</td>
</tr>
<tr>
<td>RARE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$45.00</td>
<td>$44.3K</td>
<td align="right">255</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$182.50</td>
<td>$28.8K</td>
<td align="right">780</td>
<td>752</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$100.00</td>
<td>$81.1K</td>
<td align="right">468</td>
<td>324</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$165.00</td>
<td>$79.9K</td>
<td align="right">302</td>
<td>65</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$85.00</td>
<td>$34.1K</td>
<td align="right">236</td>
<td>59</td>
</tr>
<tr>
<td>PODD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$35.7K</td>
<td align="right">5</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding INO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on November 21, 2025. Parties traded 684 contract(s) at a $2.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $45.0 per contract. There were 332 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on May 2, 2025. Parties traded 43 contract(s) at a $820.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $35.4K, with a price of $836.0 per contract. There were 141 open contracts at this strike prior to today, and today 1130 contract(s) were bought and sold. 
• For RARE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), we notice a call option sweep that happens to be bullish, expiring in 106 day(s) on August 15, 2025. This event was a transfer of 80 contract(s) at a $45.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $44.3K, with a price of $560.0 per contract. There were 255 open contracts at this strike prior to today, and today 1028 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 22 contract(s) at a $182.50 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $1310.0 per contract. There were 780 open contracts at this strike prior to today, and today 752 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 163 contract(s) at a $100.00 strike. This particular put needed to be split into 53 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $500.0 per contract. There were 468 open contracts at this strike prior to today, and today 324 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 624 day(s) on January 15, 2027. This event was a transfer of 65 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $79.9K, with a price of $1230.0 per contract. There were 302 open contracts at this strike prior to today, and today 65 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 413 day(s) on June 18, 2026. This event was a transfer of 33 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $34.1K, with a price of $1035.0 per contract. There were 236 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For PODD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), we notice a put option sweep that happens to be bullish, expiring in 260 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $260.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $35.7K, with a price of $3570.0 per contract. There were 5 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LNTH

PODD

RARE

8 Health Care Stocks Whale Activity In Today's Session

Market Summary

Benzinga Market Summary: S&P Rises Amid Strength In Microsoft And Meta Following Earnings, Lilly Cuts Outlook, Gold Pulls Back

During Conference Call Eli Lilly Exec Reportedly Says Announced Tariffs Currently In Effect Do Not Materially Change Co's 2025 Financial Outlook; Expansion Of Tariffs In Other Geographies Or Increases In Retaliatory Tariffs Would Have A Negative Effect On Co, Industry

Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading lower after the company released first-quarter earnings and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45112166/eli-lilly-stock-has-the-technicals-will-q1-earnings-deliver-fundamentals" rel="noreferrer noopener">lowered 2025 guidance</a>.
The U.S. pharma giant reported first-quarter revenue of $12.73 billion, up 45% year over year, almost in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $12.67 billion</a>, driven by a 53% increase in volume, partially offset by a 6% decrease due to lower realized prices and a 2% unfavorable impact of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45129353/lilly-reports-first-quarter-2025-financial-results-and-highlights-pipeline-momentum" rel="noreferrer noopener">foreign exchange rates</a>.
Key Products revenue grew by&nbsp;$4.09 billion&nbsp;to&nbsp;$7.52 billion&nbsp;in Q1 2025, led by Mounjaro and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" rel="noreferrer noopener">Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence</a>
Revenue in the&nbsp;U.S.&nbsp;increased 49% to&nbsp;$8.49 billion, driven by a 57% increase in volume, partially offset by a 7% decrease due to lower realized prices. Zepbound and Mounjaro drove the increase in&nbsp;U.S.&nbsp;volume.
Revenue outside the&nbsp;U.S.&nbsp;increased 38% to&nbsp;$4.24 billion, driven by a 46% increase in volume.
The volume increase outside the&nbsp;U.S.&nbsp;was driven primarily by Mounjaro and, to a lesser extent, Jardiance.
The company reported an adjusted EPS of $3.34, compared to $2.58 from a year ago, beating the consensus of $3.02.
Mounjaro sales&nbsp;jumped 113% to $3.84 billion. U.S.&nbsp;revenue was&nbsp;$2.66 billion, an increase of 75%, reflecting continued strong demand, partially offset by lower realized prices.
Revenue outside the&nbsp;U.S.&nbsp;increased to&nbsp;$1.19 billion&nbsp;compared with&nbsp;$286.2 million&nbsp;in Q1 2024, primarily driven by volume growth, including entry into new markets, partially offset by lower realized prices.
Sales of Verzenio (a breast cancer drug)&nbsp;increased 10% to&nbsp;$1.16 billion. U.S.&nbsp;revenue was&nbsp;$657.6 million, a 3% increase driven by higher realized prices. Increased demand was more than offset by wholesaler buying patterns and competitive dynamics.
Revenue outside the&nbsp;U.S.&nbsp;was&nbsp;$501.3 million, an increase of 22%, primarily driven by volume growth, partially offset by the unfavorable impact of foreign exchange rates.
Zepbound sales reached $2.31 billion, surging from $517.4 million a year ago, driven by demand growth despite pricing pressures.
Guidance: Eli Lilly reaffirms fiscal year 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines" rel="noreferrer noopener">sales of $58 billion—$61 billion</a> versus a consensus of $59.52 billion and $45.04 billion in 2024.
Eli Lilly lowers the 2025 adjusted EPS outlook from $22.50-$24.00 to $20.78-$22.28 compared to the consensus of $21.93 to reflect the impact of the Q1 2025 acquired IPR&amp;D.
In Q1 2025, the company recognized acquired in-process research and development (IPR&amp;D) charges of $1.57 billion compared with $110.5 million in Q1 2024, primarily related to acquiring Scorpion Therapeutics, Inc.'s STX-478 program.
In January, Eli Lilly agreed to acquire Scorpion Therapeutics' PI3Kα inhibitor <a target="_blank" href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion" rel="noreferrer noopener">program STX-478</a>.
STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.&nbsp;
Under the terms of the agreement, Lilly will acquire Scorpion, and Scorpion shareholders could receive up to&nbsp;$2.5 billion&nbsp;in cash. Up to $1 billion will be paid upfront, with an additional $1.5 billion contingent on meeting specific performance milestones.
Eli Lilly added that the guidance includes the existing tariff and trade environment and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business.
In an interview with CNBC, Eli Lilly CEO Dave Ricks <a target="_blank" href="https://www.cnbc.com/2025/05/01/eli-lilly-lly-earnings-q1-2025.html" rel="noreferrer noopener">said</a>, "I think that actually the threat of tariffs is already bringing back critical supply chains into important industries, chips and pharma."
"So do we need to enact [tariffs?] I'm not so sure," Ricks said.
Price Action: At last check on Thursday, LLY stock was down 6.91% to 837.26.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/05/45133096/this-is-how-much-it-will-cost-general-motors-from-trumps-tariff-policy" target="_blank" rel="noreferrer noopener">This Is How Much It Will Cost General Motors From Trump's Tariff Policy</a></li>
</ul>
Photo by M7kk via Shutterstock

Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs

MSFT: 9% &#x7C; <a href="https://www.benzinga.com//node/45128548">Microsoft shares are trading higher after the company reported Q3 financial results and beat its EPS and sales estimates. The company also issued strong revenue guidance.</a>
&nbsp;
META: 7% &#x7C; <a href="https://www.benzinga.com//node/45128558">Meta Platforms shares are trading higher following better-than-expected Q1 financial results.</a>
&nbsp;
LLY: -6% &#x7C; <a href="https://www.benzinga.com//node/45129537">Eli Lilly shares are trading lower after the company cut its FY25 EPS guidance.</a>

Market-Moving News for May 1st

WIIM

Eli Lilly shares are trading lower after the company cut its FY25 EPS guidance.

Press Releases

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

Lilly confirms date and conference call for first-quarter 2025 financial results announcement

STAAR Surgical Announces Changes to Board of Directors

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly's Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

Commodity Supercycle Spotlight: Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Expands High-Grade Copper-Gold Zone-More Stocks Under $2 Gaining Traction

Lilly reports first-quarter 2025 financial results and highlights pipeline momentum

Lilly to participate in Bank of America Securities 2025 Healthcare Conference

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly's Gene Therapy Division

Dividends

Lilly declares second-quarter 2025 dividend

Lilly announces transitions in executive leadership

BAYRY

CRVL

JFBR

MDRX

PNPNF

QSII

STAA

TSXV:PNPN

TSXV:PTFY

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Eli Lilly

매도 수량

Eli Lilly (NYSE:LLY) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌